Kajinami K - Search Results

1

Statin response and pharmacokinetics variants.

Kajinami K, Masuya H, Hoshiba Y, Takeda K, Sato R, Okabayashi M, Schaefer EJ. Kajinami K, et al. Expert Opin Pharmacother. 2005 Jul;6(8):1291-7. doi: 10.1517/14656566.6.8.1291. Expert Opin Pharmacother. 2005. PMID: 16013979 Review.

2

NK-104: a novel synthetic HMG-CoA reductase inhibitor.

Kajinami K, Mabuchi H, Saito Y. Kajinami K, et al. Expert Opin Investig Drugs. 2000 Nov;9(11):2653-61. doi: 10.1517/13543784.9.11.2653. Expert Opin Investig Drugs. 2000. PMID: 11060827 Review.

3

Cholesterol absorption inhibitors in development as potential therapeutics.

Kajinami K, Takekoshi N. Kajinami K, et al. Expert Opin Investig Drugs. 2002 Jun;11(6):831-5. doi: 10.1517/13543784.11.6.831. Expert Opin Investig Drugs. 2002. PMID: 12036426 Review.

4

Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.

Kajinami K, Takekoshi N, Saito Y. Kajinami K, et al. Cardiovasc Drug Rev. 2003 Fall;21(3):199-215. doi: 10.1111/j.1527-3466.2003.tb00116.x. Cardiovasc Drug Rev. 2003. PMID: 12931254 Review.

5

Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia.

Kajinami K, Takekoshi N, Matsui S, Kanemitsu S, Okubo S, Kanayama S, Yamashita N, Sato R. Kajinami K, et al. Am J Cardiol. 2003 Nov 1;92(9):1113-6. doi: 10.1016/j.amjcard.2003.06.011. Am J Cardiol. 2003. PMID: 14583368 Clinical Trial.

6

CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.

Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Kajinami K, et al. Am J Cardiol. 2004 Jan 1;93(1):104-7. doi: 10.1016/j.amjcard.2003.08.078. Am J Cardiol. 2004. PMID: 14697480

7

ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin.

Kajinami K, Brousseau ME, Nartsupha C, Ordovas JM, Schaefer EJ. Kajinami K, et al. J Lipid Res. 2004 Apr;45(4):653-6. doi: 10.1194/jlr.M300278-JLR200. Epub 2004 Jan 1. J Lipid Res. 2004. PMID: 14703505 Free article.

8

Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner.

Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Kajinami K, et al. Am J Cardiol. 2004 Apr 15;93(8):1046-50. doi: 10.1016/j.amjcard.2004.01.014. Am J Cardiol. 2004. PMID: 15081455

9

Imbalance of sex hormone levels in men with coronary artery disease.

Kajinami K, Takeda K, Takekoshi N, Matsui S, Tsugawa H, Kanemitsu S, Okubo S, Kitayama M, Fukuda A. Kajinami K, et al. Coron Artery Dis. 2004 Jun;15(4):199-203. Coron Artery Dis. 2004. PMID: 15187571

10

Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin.

Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Kajinami K, et al. Atherosclerosis. 2004 Aug;175(2):287-93. doi: 10.1016/j.atherosclerosis.2004.03.015. Atherosclerosis. 2004. PMID: 15262185

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

143 results

Search Page

Filters